News|Articles|August 21, 2009

NIR Prediction of Solid Dosage Form Dissolution Profiles - Foss Whitepaper

External Link - article-620799.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision

ByZachary Zubulake,Christopher Cole

June 3rd 2026

Adeno-associated virus. AAV virus genome. Adenoviral pneumonia, arthritis, bronchitis, hepatitis, cystitis. Adenovirus as vectors for gene therapy. Genetic material transmission to cell. Biotech 3D | Image Source: ©Corona Borealis -stock.adobe.com

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

ByJohn Muganga

June 3rd 2026

Generic GLP-1s Enter Canadian Market

ByErez Israeli,Susan Haigney

June 2nd 2026

Implications of Pediatric Inhaled Insulin Approval

ByZachary Zubulake

June 1st 2026

PharmTech Weekly Roundup—May 29, 2026

BySusan Haigney

May 29th 2026

NIR Prediction of Solid Dosage Form Dissolution Profiles - Foss Whitepaper

Related Content

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

Generic GLP-1s Enter Canadian Market

Implications of Pediatric Inhaled Insulin Approval

PharmTech Weekly Roundup—May 29, 2026

Trending on Pharmaceutical Technology

Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision

Generic GLP-1s Enter Canadian Market